Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform…
<!-- Name:DistributionId Value:8741131 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
AlloCAR
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances…
Hematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in…
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single…
ALLO-715 UNIVERSAL Trial is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety and Substantial Efficacy in Multiple Myeloma Updated Data Demonstrate Responses Similar to Approved…